Compare · ISRG vs NTRB
ISRG vs NTRB
Side-by-side comparison of Intuitive Surgical Inc. (ISRG) and Nutriband Inc. (NTRB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ISRG and NTRB operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ISRG is the larger of the two at $151.74B, about 2148.6x NTRB ($70.6M).
- ISRG has been more active in the news (12 items in the past 4 weeks vs 1 for NTRB).
- ISRG has more recent analyst coverage (25 ratings vs 1 for NTRB).
- Company
- Intuitive Surgical Inc.
- Nutriband Inc.
- Price
- -
- -
- Market cap
- $151.74B
- $70.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 12
- 1
- Recent ratings
- 25
- 1
Intuitive Surgical Inc.
Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.
Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Latest ISRG
- EVP & Chief Legal and Complian Loeb Gary sold $183,260 worth of shares (400 units at $458.15) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 6,236 units (SEC Form 4)
- Director Guthart Gary S sold $4,573,370 worth of shares (10,000 units at $457.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Barratt Craig H exercised 1,150 shares at a strike of $90.49 and sold $529,003 worth of shares (1,150 units at $460.00) as part of a pre-agreed trading plan (SEC Form 4)
- Intuitive Surgical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Intuitive Appoints Aaron Martin to its Board of Directors
- EVP & Chief Mfg and Supply Cha Brosius Mark sold $55,896 worth of shares (124 units at $450.77) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 457 units (SEC Form 4)
- VP Corporate Controller Widman Fredrik exercised 5,448 shares at a strike of $201.07 and sold $2,375,628 worth of shares (5,448 units at $436.06) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & Chief Mfg and Supply Cha Brosius Mark sold $82,044 worth of shares (183 units at $448.33) as part of a pre-agreed trading plan (SEC Form 4)
- Director Barratt Craig H sold $510,370 worth of shares (1,150 units at $443.80) as part of a pre-agreed trading plan (SEC Form 4)
- VP Corporate Controller Widman Fredrik sold $1,834,124 worth of shares (4,047 units at $453.21) as part of a pre-agreed trading plan (SEC Form 4)
Latest NTRB
- Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System
- Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
- Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
- Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
- SEC Form 25-NSE filed by Nutriband Inc.
- Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
- Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
- Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
- Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch